



## Supplementary Figure 2

### eIF5A1: 201122\_x\_at



### eIF5A2: 220198\_s\_at



**Supplementary Figure 2.** Relative expression levels of eIF5A1 and eIF5A2 in 177 endometrial cancers. Geometric mean values and standard errors of Affymetrix transcripts 201122\_x\_at and 220198\_s\_at (where the expression data were normalized to a mean transcript level of array to 500). No differential expression was found to be statistically significant ( $p > 0.05$ ). Ratios: A. Endometrioid Adv / Early = 1.12 ( $p = 0.32$ ), Serous Adv / Early = 0.75 ( $p = 0.06$ ), Adv = FIGO Stage IIIC – IVB, n = number of cases; Early = FIGO Stage IA – IIIA; B. Endometrioid G3 / G2 = 1.12 ( $p = 0.21$ ), Serous G3 / G2 = 0.95 ( $p = 0.86$ ); C. Endometrioid Adv / Early = 0.85 ( $p = 0.56$ ), Serous Adv / Early = 0.92 ( $p = 0.81$ ); D. Endometrioid G3/G2 = 1.27 ( $p = 0.27$ ), Serous G3 / G2 = 1.10 ( $p = 0.86$ ).